Profile data is unavailable for this security.
About the company
Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company. The Company is focused on commercializing generic pharmaceuticals. The Company operates through three segments: International, Branded Products Division (BPD) and Portfolio Products Division (PPD). Its International segment manufactures and sells branded and generic pharmaceutical product globally and the provision of contract development and manufacturing services to third party customers. The BPD segment distributes medically differentiated specialty products in United States. The PPD segment distributes established products (branded and generic) in the United States on a portfolio basis. The Company's products include Doxycycline Capsules, Oxycodone IR Tablets, Erythromycin Capsules and others.
- Revenue in AUD (TTM)278.45m
- Net income in AUD-258.82m
- Incorporated2005
- Employees900.00
- LocationMayne Pharma Group Ltd1538 Main North RdADELAIDE 5106AustraliaAUS
- Phone+61 88209-2666
- Fax+61 88281-0284
- Websitehttp://www.maynepharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Botanix Pharmaceuticals Ltd | 200.38k | -10.02m | 346.53m | 1.00 | -- | 7.50 | -- | 1,729.37 | -0.0072 | -0.0072 | 0.0002 | 0.0293 | 0.0059 | -- | 1.09 | -- | -29.28 | -67.71 | -32.25 | -81.15 | -- | -- | -5,002.57 | -8,798.51 | 8.14 | -138.17 | 0.00 | -- | 351.94 | -6.25 | 30.50 | -- | -- | -- |
PYC Therapeutics Ltd | 21.54m | -21.65m | 428.79m | 23.00 | -- | 10.36 | -- | 19.90 | -0.006 | -0.006 | 0.0062 | 0.008 | 0.6034 | -- | 2.48 | -- | -60.70 | -41.67 | -81.23 | -46.95 | -- | -- | -100.60 | -178.69 | -- | -50.32 | 0.0174 | -- | -1.11 | 218.52 | -64.39 | -- | 18.46 | -- |
Immutep Ltd | 256.62k | -40.50m | 439.87m | 19.00 | -- | 3.80 | -- | 1,714.09 | -0.0394 | -0.0394 | 0.0003 | 0.0973 | 0.0025 | -- | 2.48 | -- | -38.61 | -36.31 | -41.57 | -39.21 | -- | -- | -15,782.59 | -919.13 | -- | -- | 0.0138 | -- | -24.64 | -51.34 | -23.86 | -- | 47.40 | -- |
Opthea Ltd | 179.27k | -247.41m | 490.48m | 5.00 | -- | -- | -- | 2,735.97 | -0.4742 | -0.4742 | 0.0004 | -0.1084 | 0.0007 | -- | 0.1772 | -- | -100.84 | -90.04 | -116.05 | -100.93 | -99.74 | -197.19 | -138,008.10 | -69,641.71 | -- | -29.64 | 1.35 | -- | 19.55 | -34.31 | -53.55 | -- | -3.82 | -- |
Mesoblast Ltd | 11.43m | -111.85m | 564.65m | 83.00 | -- | 0.645 | -- | 49.40 | -0.1356 | -0.1356 | 0.014 | 0.7675 | 0.0112 | -- | 3.71 | 137,709.00 | -10.92 | -12.66 | -11.67 | -13.92 | -190.91 | -78.09 | -978.54 | -593.91 | -- | -3.01 | 0.1934 | -- | -26.56 | -15.43 | 10.35 | -- | 5.60 | -- |
Mayne Pharma Group Ltd | 278.45m | -258.82m | 614.24m | 900.00 | -- | 1.07 | -- | 2.21 | -3.18 | -2.99 | 3.43 | 6.74 | 0.2105 | 0.8192 | 1.37 | -- | -19.56 | -14.47 | -26.66 | -18.05 | 68.05 | 50.60 | -92.95 | -64.69 | 1.30 | -5.68 | 0.0626 | -- | 20.75 | -18.54 | -51.49 | -- | 18.41 | -- |
Clinuvel Pharmaceuticals Limited | 87.46m | 30.15m | 710.80m | 16.00 | 24.34 | 3.98 | 22.82 | 8.13 | 0.5825 | 0.5825 | 1.69 | 3.56 | 0.4702 | -0.9514 | 7.37 | -- | 16.21 | 21.25 | 18.57 | 23.55 | 109.26 | -- | 34.48 | 41.84 | 6.43 | 12.11 | 0.006 | 7.44 | 24.27 | 26.14 | 46.58 | 18.27 | 68.74 | 20.11 |
Clarity Pharmaceuticals Ltd | 11.80m | -30.56m | 749.91m | -- | -- | 14.09 | -- | 63.55 | -0.117 | -0.117 | 0.0452 | 0.2023 | 0.1596 | -- | 0.8407 | -- | -41.34 | -- | -45.22 | -- | -- | -- | -258.98 | -- | -- | -- | 0.00 | -- | 77.98 | -- | -3.57 | -- | -- | -- |
Imugene Ltd | 0.00 | -89.24m | 768.43m | 0.00 | -- | 3.86 | -- | -- | -0.0132 | -0.0132 | 0.00 | 0.0272 | 0.00 | -- | -- | -- | -40.29 | -26.64 | -43.53 | -28.00 | -- | -- | -- | -- | -- | -- | 0.021 | -- | -- | -- | -0.1207 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Investors Mutual Ltd.as of 10 Aug 2022 | 4.40m | 5.18% |
Rubric Capital Management LPas of 18 Sep 2023 | 4.36m | 5.12% |
Lazard Asset Management Pacific Co.as of 13 Jun 2023 | 4.24m | 4.99% |
The Vanguard Group, Inc.as of 07 Mar 2024 | 2.81m | 3.31% |
Dimensional Fund Advisors LPas of 07 Mar 2024 | 1.22m | 1.43% |
Vanguard Investments Australia Ltd.as of 29 Feb 2024 | 1.18m | 1.39% |
UBS AG (Investment Management)as of 14 Mar 2024 | 640.13k | 0.75% |
DFA Australia Ltd.as of 29 Feb 2024 | 637.17k | 0.75% |
Norges Bank Investment Managementas of 31 Dec 2023 | 555.30k | 0.65% |
UBS Asset Management (Australia) Ltd.as of 14 Mar 2024 | 478.45k | 0.56% |